News Center

Bombardier’s quarterly revenue rises 19% on delivery strength, higher services revenue

Bombardier’s quarterly revenue rises 19% on delivery strength, higher services revenue

By Dan Catchpole and Aatreyee Dasgupta (Reuters) - Canadian business jet manufacturer Bombardier (OTC:BDRBF) reported higher first-quarter revenue on Thursday, owing to increased aircraft deliveries and growth in aftermarket services, but the company’s gains fell slightly short of investor expectations. Bombardier President and CEO Eric Martel said he sees more opportunities than dangers amid th ...

2025-05-01 21:57:00
GM cuts 2025 profit forecast as expects up to $5 billion impact tariff hit

GM cuts 2025 profit forecast as expects up to $5 billion impact tariff hit

By Kalea Hall DETROIT (Reuters) - General Motors (NYSE:GM) cut its 2025 profit forecast on Thursday after receiving some clarity and a reprieve from the White House this week on automotive tariffs. CEO Mary Barra told shareholders in a letter that the company would maintain dialogue with the Trump administration on trade and other policies as they evolve.  "There are ongoing discussions ...

2025-05-01 21:56:02
Thomson Reuters reaffirms 2025 financial forecasts amid economic turmoil

Thomson Reuters reaffirms 2025 financial forecasts amid economic turmoil

By Kenneth Li (Reuters) - Thomson Reuters (NYSE:TRI) on Thursday reaffirmed 2025 financial guidance amid tariff-induced global economic turmoil that has led some companies to revise or scrap forecasts altogether. The Toronto-based content and technology company reported quarterly revenue rising 1% to $1.9 billion, slightly below analyst expectations of $1.93 billion, according to LSEG data. Orga ...

2025-05-01 21:55:01
Eli Lilly’s weight-loss drug sales miss expectations, shares fall

Eli Lilly’s weight-loss drug sales miss expectations, shares fall

(Reuters) - Eli Lilly (NYSE:LLY) on Thursday posted better-than-expected quarterly results, although sales of its popular weight-loss drug, Zepbound, came in slightly below Wall Street estimates, sending its shares down 4% in premarket trading. Separately, CVS Health (NYSE:CVS) said that its pharmacy benefit management unit would drop Lilly’s Zepbound as a preferred product from its list of drug ...

2025-05-01 21:53:54